Abstract Rehabilitation technologies offer promising opportunities for interventions for patients with motor disabilities. However, their use in routine care remains limited due to their high cost and persistent doubts about their cost-effectiveness. Providing solid evidence of the economic efficiency of rehabilitation technologies would help dispe...
Published in The European journal of health economics : HEPAC : health economics in prevention and care
The value of a Quality-Adjusted Life-Year (QALY) is of great importance for the healthcare system. It helps when it comes to defining a cost-effectiveness threshold for the evaluation of health technologies. No willingness-to-pay value for a QALY exists in the province of Quebec, Canada. In this paper, we empirically investigated the monetary value...
BACKGROUND: When formulating and evaluating COVID-19 vaccination strategies, an emphasis has been placed on preventing severe disease that overburdens healthcare systems and leads to mortality. However, more conventional outcomes such as quality-adjusted life years (QALYs) and inequality indicators are warranted as additional information for policy...
Published in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Quality-adjusted life-year (QALY) is a dominant measurement of health gain in economic evaluations for pricing drugs. However, end-of-life (EoL) patients' preference for QALY gains in life expectancy (LE) and quality of life (QoL) during different disease stages remains unknown and is seldom involved in decision-making. This study aims to measure p...
Funder: Università degli Studi di Trieste / PURPOSE: The aim of this study was to provide an updated European narrative review spanning the last decade, focusing on the cost-effectiveness of cochlear implants (CIs) for adults with severe to profound post-lingual hearing loss. METHODS: This review encompasses both prospective and retrospective appro...
Bien que l’évaluation économique de la santé en France se concentre sur une analyse coût-efficacité basée sur les QALY depuis 10 ans, aucune valeur de référence pour qualifier le rapport coût-efficacité différentiel (ICER) n’a été définie. Ce statu quo est clairement lié à l’absence de consensus sur l’utilisation d’une valeur de référence pour l’év...
Published in Expert review of pharmacoeconomics & outcomes research
The United States has begun assessing the value of pharmaceuticals to inform negotiated prices in the Medicare program. Given strong political objections in the United States to the use of QALYs, Medicare will need to adopt an alternative approach to measuring value. In this narrative review, we identified six alternative approaches to measuring va...
Published in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Patient-reported outcome measures (PROMs) are commonly collected in trials and some care settings, but preference-based PROMs required for economic evaluation are often missing. For these situations, mapping models are needed to predict preference-based (aka utility) scores. Our objective is to develop a series of mapping models to predict preferen...
Les systèmes français et britanniques d’évaluations et de tarifications des médicaments reposent sur des flux et des concepts opposés. Du côté français, l’accès aux médicaments commencent par une évaluation clinique orchestrée par la commission de la transparence qui émet un « avis » sur le SMR et l’ASMR (c.à.d. une évaluation clinique relativement...
Published in The European journal of health economics : HEPAC : health economics in prevention and care
Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data...
